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Serine protease inhibitors have important regulatory 
roles in angiogenesis, intravascular fibrinolysis, 
wound healing, and cell migration. In this study, the 
extracellular matrix secreted by cultured human ke-
ratinocytes, foreskin fibroblasts, and SV -40 -trans-
formed human skin fibroblasts was analyzed for 
serine protease inhibitors by substrate reverse zy-
mography . We found that the extracellular matrix 
deposited by these cells contained three inhibitors 
(Mr 33,000, 31,000, and 27,000). These inhibitors pro-
tected the degradation of gelatin by trypsin and 
elastase, and of casein by plasmin. In contrast, the 
gelatinolytic activities of thermolysin and papain 
were not inhibited. Compared to untreated cells, 
ecently, the extracellular matrix (ECM) secreted 
by fibroblasts and endothelial cells has been shown 
to function as a reservoir of growth factors, en-
zymes, and inhibitors. For example, plasminogen 
activator inhibitor-1 (PAI-1) is found to be associ-
ated fIrmly with the ECM [1,2] . Vitronectin in the ECM is 
responsible for the binding of PAI-1 [3]. The ECM association of 
PAI-1 has been suggested to have physiologic significance. ECM-
bound PAI- 1, unlike soluble PAI- 1, is protected from inactivation 
and remains active for long periods [4]. The target enzymes for 
PAI- 1 are urokinase and tissue plasminogen activator, which also 
are associated with the ECM [5,6]. 
ECM remodeling plays a major role in wound healing, angio-
genesis, embryogenesis, and cell migration. ECM remodeling in-
volves a fme balance between proteases and their inhibitors. Two 
classes of proteases- matrix metalloproteases (MMPs) and serine 
proteases- are particularly important in the degradation of ECM 
[7]. MMPs-1, 2, 3, and 9 have been characterized [8], along with 
their specific tissue inhibitors [9,10]. Of the serine proteases, 
urokinase and plasmin are of primary importance in ECM degra-
dation [11]. Urokinase is secreted by keratinocytes, fibroblasts, and 
endothelial cells [12-14]; it binds to cell receptors and converts 
plasminogen to plasmin, a protease involved in ECM degradation 
[11]. PAI-1 and PAI-2 inhibit urokinase but do not inhibit plasmin 
[15]. The inhibitors for plasmin and related serine proteases (trypsin 
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cells treated with phorbol 12-myristate 13-acetate 
showed a two- to 10-fold increase in the expression of 
these inhibitors. Cycloheximide and actinomycin D 
decreased the cellular expression of these inhibitors, 
suggesting the involvement of de novo protein and 
mRNA synthesis. Antitrypsin activity of these inhib-
itors was resistant to heat and sodium dodecylsulfate, 
but was lost after reduction of disulfide bonds. The 
inhibitors bound specifically to trypsin and could be 
eluted from a trypsin column in active form. Collec-
tively, these data suggest that the extracellular ma-
trix deposited by keratinocytes and dermal fibroblasts 
contains active serine protease inhibitors. ] Invest 
D evmatol 104:379-383, 1995 
and elastase) have not been identified in human skin cells. Cathep-
sin B, a thiol-protease [16], and cathepsin D, an acid-protease, are 
also active in degradation of the ECM [17]. 
In this study, we partially characterized serine protease inhibitors 
that are associated with the ECM and synthesized and deposited by 
skin cells. Extracts of ECM from normal human keratinocytes, 
human foreskin fibroblasts, and SV-40-transformed human fore-
skin fibroblasts (t12 fibroblasts) contain three protease inhibitors 
(Mr 33-, 31-, and 27-kDa). These inhibitors protect gelatin from 
degradation by trypsin and elastase. They also protect the degrada-
tion of casein by plasmin. The degradation of gelatin by thermolysin 
and papain is not decreased by these inhibitors. 
MATERIALS AND METHODS 
Materials Bovine pancreatic trypsin, porcine pancreatic elastase, human 
plasma plasmin, phorbol 12-myristate 13-acetate (PMA) , cycloheximide, 
and actinomycin D were purchased from Sigma Chemical Co. (St. Louis, 
MO). Papain and thermolysin were purchased from Boehringer Mannheim 
Biochemicals (Indianapolis, IN) . Reactigel affinity matrix was obtained 
from Pierce Chemical Co. (Rockford, IL). Bovine casein and calf skin 
gelatin were obtained from ICN Biochemicals (Irvine, CA). RPMI, Dul-
becco's modification of Eagle's medium, F12 medium, glutamine, fetal 
bovine serum, and trypsin-ethylenediamine tetraacetic acid were purchased 
from Northwestern University Cancer Center, Tissue Culture Facility. 
Growth supplements for culturing keratinocytes were purchased from 
Clonetics Inc. (San Diego, CA) . 
Cell Culture Conditions Neonatal foreskin was the source of fibroblast 
and keratinocyte cells, cultured by the method ofKahaleh et al [18] and the 
method of Boyce and Ham [19] as modified by O'Keefe and Chiu [20] , 
respectively. Both fibroblasts and keratinocytes were used in their second or 
third passage for obtaining the ECM for analysis by reverse zymography. t12 
fibroblasts were cultured in RPMI containing 10% fetal bovine serum, 50 
I-Lg penicillin, and 50 I-Lg/ml streptomycin [21]. 
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Figure 1. Increased expression of 33-kDa, 31-kDa, and 27-kDa trypsin inhibitors in the ECM of PMA (100 ng/ml)-treated keratinocytes, 
fibroblasts, and tt2 fibroblasts. CM and ECM extracts from control and PMA-treated cells were analyzed by SDS-PAGE (A,C,E) and by substrate reverse 
zymography with trypsin (B,D,F), as described in Materials and Methods. A,B: lane 1 (10 J-tg) and lane 3 (0.2 J-tg) are CM and ECM from untreated keratinocytes, 
respectively; lane 2 (10 J-tg) and lane 4 (0.2 J-tg) are CM and ECM from PMA-treated keratinocytes, respectively. C,D: lane 1 (0.5 J-tg) and lane 3 (0.2 J-tg) 
are CM and ECM from untreated fibroblasts, respectively; larze 2 (0.5 J-tg) and lane 4 (0.2 J-tg) are CM and ECM from PMA-treated fibroblasts, respectively. 
B,F: lane 1 (1 J-tg) and lane 3 (0.2 J-tg) are CM and ECM from untreated t12 fibroblasts, respectively; lane 2 (1 J-tg) and lane 4 (0.2 J-tg) are CM and ECM from 
PMA-treated t12 fibroblasts, respectively. Lanes MW, molecular weight markers. Antitrypsin activity was clearly evident for proteins of 33 kDa, 31 kDa 
(arrowheads), and 27 kDa from the ECM extracts but not from the CM of keratinocytes, fibroblasts, and t12 fibroblasts . 
Preparation of Serum-Free Conditioned Medium (CM) and ECM 
Cells were grown to subconfluence in 100-mm tissue culture dishes. In 
certain experiments, the growth medium was replaced with fresh medium 
supplemented with PMA alone or in combination with cycloheximide or 
actinomycin D, at concentrations indicated (see Figs). The control cells 
were treated with dimethylsulfoxide, which was used to solubilize PMA, 
cycloheximide, and actinomycin D. The control and PMA-incubated cells 
were cultured overnight, the medium was discarded, and the cell mono-
layers were rinsed three times with phosphate-buffered saline. The cells 
were then cultured in serum-free unconditioned medium for an additional 
20 h , and the CM was collected. In the case of keratinocytes, the growth 
medium containing bovine pituitary extract and other growth additives was 
used to collect the CM. The CM was cleared of cell debris by centrifugation 
(1200 X g for 5 min) and processed for substrate reverse zymography. 
In experinlents involving the use of cycloheximide and! or actinomycin 
D, t12 fibroblasts were allowed to grow for 2 d and then treated with the 
drugs for 20 min at concentrations of1.0 J-tM and 100 nM, respectively. The 
cells were then treated with PMA and incubated for an additional 20 h. The 
medium was discarded and the ECM prepared as described below. 
The ECM was prepared as described previously [22] . Briefly, the cell 
monolayers were washed three times with phosphate-buffered saline, then 
removed by incubation at room temperature for 20 min in 10 ml of 
phosphate-buffered saline containing 0.5% (v!v) Triton X-100. The re-
maining ECM was washed three times with 20 mM Tris-HCI, pH 7.4, 
containing 100 mM NaCI and 0.1% (v/v) Tween-20, and two times with 
phosphate-buffered saline. After these washings, no cells were found in the 
culture dishes by light microscopy. The ECM prepared in this manner has 
been shown to be devoid of nuclei or cytoskeletal elements (actin and 
vimentin) by phase-contrast microscopy, scanning electron microscopy, and 
indirect immunofluorescence [23). 
Processing of CM and ECM for Substrate Reverse Zymography 
Twenty-four milliliters of CM was mixed with an equal volume of saturated 
alllmonium sulfate solution and incubated overnight at 4°C with end-over-
end rotation. The proteins were pelleted by centrifugation (22,700 X g at 
4°C for 30 min) and dissolved in 2 ml of 10 mM Tris-HCI, pH 7.40. Salt 
removal and further concentration of the proteins (final volume 200 J-tl) 
were achieved using Amicon YM-10 centricon devices. The protein 
content was determined according to Bradford [24] using a standard curve 
plotted against bovine serum albumin (BSA). 
The ECM-bound proteins were extracted into 3 ml of a buffer containing 
0.1 M glycine-HCI, pH 2.5, for 30 min at room temperature. The extract 
was neutralized immediately with 1.5 M Tris-HCI, pH 8.8, and concen-
trated to a final volume of 200 J-tl, as described above. This procedure has 
been shown to be useful for extracting PAI-1 from ECM in active form 
[4,22]. 
Affinity Chromatography Trypsin and BSA (2 mg/ml) were coupled to 
Reactigel affinity beads following the manufacturer's recoll1ll1ended proce-
dure (Pierce Chemical Co.) . Ethanolamine-blocked beads were prepared 
simultaneously. Ten milliliters of ECM extract from PMA-treated t12 
fibroblasts was incubated at room temperature with 100 J-tl trypsin, BSA, or 
ethanolaDline-blocked affinity beads, which were equilibrated previously in 
10 mM Tris-HCl, pH 7.40 (equilibration buffer). The incubation was 
continued for 1 h with end-over-end rotation. The extract containing the 
unbound proteins was collected, and the affinity beads were washed four 
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Figure 2. ECM-associated trypsin inhibitors 
inhibit elastase and plasmin, but not thermo-
lysin. Acid-eluted proteins from the ECM of un-
treated (50-fold concentrate) and PMA-treated t12 
fibroblasts (50-fold concentrate) were submitted to 
gelatin reverse zymography with elastase (A), casein 
reverse zymography with plasmin (B), and gelatin 
reverse zymography with thermolysin (C). Lanes 
MW, molecular weight markers. Lanes 1, untreated 
(004 /-tg), and lanes 2, PMA-treated t12 fibroblasts 
(0.3 /-tg). Undergraded substrate bands of 33 kDa, 
31 kDa, and 27 kDa (arrOluheads) were evident from 
the ECM extracts of t12 fibroblasts after reverse 
zymography with elastase and plasmin, but not with 
thermolysin. 
~ ~ 45 -~ 31 - ~ 31 ~ ~ 31 -
21 21 
14 14 21 -
14 -
times with equilibration buffer. The bound proteins were eluted in 100 /-tl of 
Laemmli's sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer [25] without {3-mercaptoethanol. The proteins were 
analyzed by SDS-PAGE and substrate reverse zymography. 
SDS-PAGE and Substrate Reverse Zytnography SDS-PAGE was 
performed as described before [25] using 15% mini-slab gels under nonre-
ducing conditions, unless otherwise indicated. 
Substrate reverse zymography was performed as described previously [26] 
using polyacrylamide gels containing gelatin (2.3 mg/ml) or casein (0.6 
mg/ml). Briefly, thp. substrate gels were agitated for 60 min in 10 mM 
Tris-HC1, pH 704, containing 2% Triton X-l00, and rinsed immediately two 
times (2 X 5 min) in 10 mM Tris-HC1, pH 7 A (incubation buffer). Substrate 
was degraded by incubating the gel in 25 ml of incubation buffer containing 
one of the following enzymes: 250 /-tg trypsin (4 h), 250 /-tg elastase (3 h), 
1 mg plasmin (24 h), or 500 /-tg papain (3 h). Thermolysin was dissolved in 
incubation buffer containing 5 mM CaCI2 , and 250 /-tg of thermolysin was 
used to degrade gelatin in 2 h. The enzyme-resistant substrate bands were 
visualized by Coomassie blue staining. The protein bands were quantitated 
by densitometric analysis. 
RESULTS 
Detection ofECM-Associated Trypsin Inhibitors From Hu-
man Skin Cells To identify inhibitors that impede the gelatino-
lytic activity of trypsin, we analyzed CM and acid extracts ofECM 
by SDS-PAGE (Fig tA,e,E) and reverse zymography (Fig 
tB,D,F). SDS-PAGE of the CM from untreated keratinocytes (Fig 
tA, lane 1) and PMA-treated keratinocytes (Fig tA, lane 2) 
revealed a number of proteins with molecular sizes between 10 and 
100 kDa. To investigate whether these proteins are from the bovine 
pituitary extract and other growth additives in the keratinocyte 
culture medium, we concentrated the proteins from 10 ml of this 
medium (final volume 200 I1J), as described in Materials and 
Methods. An aliquot containing 4 J.Lg of proteins was analyzed by 
SDS-PAGE. The profile of proteins from the keratinocyte uncon-
ditioned medium (gel not shown) was similar to that of the proteins 
from untreated (Fig tA, lane 1) and PMA-treated (Fig tA, lane 2) 
keratinocyte CM. Therefore, the proteins visualized by Coomassie 
blue (between 10 and 100 kDa) were from the bovine pituitary 
extract and other growth additives in the keratinocyte culture 
medium. The CM from untreated or PMA-treated fibroblasts (Fig 
te, lanes 1,2) and untreated or PMA-treated t12 fibroblasts (Fig lE, 
lanes 1,2) did not reveal any protein smaller than 45 kDa. Similarly, 
the extracts of ECM from untreated or PMA-treated keratinocytes 
(Fig tA, lanes 3,4), untreated or PMA-treated fibroblasts (Fig 1 e, 
lanes 3,4), and control or PMA-treated t12 fibroblasts (Fig tE, lanes 
3,4) did not reveal proteins smaller than 45 kDa by SDS-PAGE. 
In contrast to the SDS-PAGE results, analysis of the ECM 
extracts by reverse zymography demonstrated two proteins (Mr 33-
and 31-kDa) capable of protecting gelatin in the gel from degra-
dation by trypsin (Fig tB,D,F; lanes 3,4). A minor band at 27 kDa 
was also detected (Fig tB,D,F; lane 4). These inhibitor bands were 
detected to varying degrees in the ECM of all three cell types, and 
the expression was enhanced up to 10-fold when PMA was added 
to the cultures (Fig tB,D,F; lane 4, compared to lane 3. In contrast 
to the ECM extracts, the CM from all these cells did not contain the 
33-kDa and 31-kDa trypsin inhibitors (Fig tB,D,F; lanes 1,2). 
Further, the inhibitors were not detected in the cell lysates of 
untreated or PMA-treated keratinocyte, fibroblast, and t12 fibro-
blast cultures (data not shown). Likewise, the unconditioned 
growth media used for the cell cultures did not contain these 
inhibitors. In certain reverse zymograms (Fig tB, lanes 1,2; D, lanes 
1,2,3,4; and F, lanes 1,2), proteins of Mr 53 kDa and higher were 
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Figure 3. Cycloheximide and actinomycin D inhibit the expression 
of 33-kDa, 31-kDa, and 27-kDa serine protease inhibitors in PMA-
treated tt2 fibroblasts. Both cycloheximide (1.0 /-tM) and actinomycin D 
(100 nM) were added to t12 cell monolayers 20 min before the addition of 
100 ng/mL ofPMA. The cell cultures were incubated overnight. Extracts of 
ECM were prepared as described in Materials and Methods and analyzed by 
gelatin reverse zymography with trypsin. Lane MW, molecular weight 
markers; lane 1, ECM from untreated t12 fibroblasts; lane 2, ECM from 
PMA-treated t12 fibroblasts; lane 3, ECM from PMA-treated t12 fibroblasts 
in the presence of cycloheximide; lane 4, ECM from PMA-treated t12 
fibroblasts in the presence of actinomycin D. 
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Figure 4. ECM-associated inhibitors bind specifically to trypsin. 
One milliliter of the ECM extract from PMA-treated t12 fibroblasts was 
incubated for 1 h with 100 p.,L of affinity matrix containing trypsin, BSA, or 
ethanolamine. The bound proteins were eluted in 100 p.,l of SDS-PAGE 
sample buffer. Antitrypsin activity was analyzed by gelatin reverse zymog-
raphy. Lane MW, molecular weight markers; lane 1, t12 ECM extract (200 
ng); lane 2, trypsin-bound fraction; lane 3, BSA-bowld fraction; lane 4, 
ethanolamine-bound fraction . 
observed. These bands are serum serine protease inhibitors such as 
al-antitrypsin and al-antichymotrypsin, as determined by reverse 
zymography using these purified inhibitors. These inhibitors have 
molecular sizes of 53 kDa and greater, and resist degradation by 
trypsin during reverse zymography (data not shown). 
ECM-Associated Trypsin Inhibitors also Inhibit Elastase 
and PlaslDin The ability of the 33-kDa, 31-kDa, and 27-kDa 
trypsin inhibitors to protect gelatin degradation by elastase, ther-
molysin, and papain, or the degradation of casein by plasmin, was 
also investigated. As shown in Fig 2, the gelatinolytic activity of 
elastase (Fig 2A, lanes 1,2) and the caseinolytic activity of plasmin 
(Fig 2B, lanes 1,2) were decreased by the ECM-associated inhibi-
tors. In contrast, the gelatinolytic activities of thermolysin (Fig 2C, 
lane 1) and papain (gel not shown) were not inhibited. Therefore, 
these inhibitors inhibit serine proteases (trypsin , elastase, and 
plasmin) but not metal-requiring enzymes or thiol-proteases. A 
protein band at Mr 53 kDa (Fig 2A, lanes 1,2) also was observed. 
This band is al-antitrypsin, as determined using pure inhibitor, 
which resists degradation by neutrophil and pancreatic elastases 
(data not shown). 
PMA-StilDulated Expression of Inhibitors Requires New 
Protein and IDRNA Synthesis To evaluate whether the stim-
ulatory effect of PMA on expression of the inhibitors required de 
novo protein and mRNA synthesis, we incubated t12 fibroblasts in 
the presence of cycloheximide and/or actinomycin D and analyzed 
the deposited ECM by substrate reverse zymography. In unstimu-
lated cells, there was low or undetectable (Fig 3, Lane 1) expression 
of the inhibitors. In contrast, when the t12 fibroblasts were 
stimulated with PMA, a high level of expression was always 
detected (Fig 3, lane 2). The expression of the inhibitors in 
PMA-treated t12 fibroblasts was decreased to undetectable levels in 
the presence of either cyclohexirrllde (Fig 3, lane 3) or actinomycin 
D (Fig 3, lane 4). These data demonstrate that PMA stimulated the 
expression of the 33-kDa and 31-kDa inhibitors at both the 
transcriptional and translational levels. 
The Inhibitors Bind to Trypsin but not to BSA The binding 
of the ECM-associated inhibitors to trypsin was assessed by trypsin 
affinity chromatography. The ECM extract from PMA-treated t12 
fibroblasts was incubated with Reactigel beads containing trypsin, 
BSA, or ethanolarrllne. The bound proteins were eluted in Lae-
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Figure 5. Reduction of disulfide bonds but not heat denaturation 
destroys antitrypsin activity of ECM-associated trypsin inhibitors. 
ECM extract of PMA-treated t12 fibroblasts was subjected to heat and 
dithiothreitol treatments, and antitrypsin activity was assessed by gelatin 
reverse zymography. Lane MW, molecular weight markers; lane 1, ECM 
extract from t12 fibroblasts (0 .2 p.,g); lane 2, ECM extract from t12 
fibroblasts (0.2 p.,g) boiled for 5 min; lane 3, ECM extract boiled in the 
presence of2 mM dithiothreitol; lane 4, ECM extract boiled for 5 min in the 
presence of 5 mM dithiothreitol. 
mmli's SDS-PAGE sample buffer without {3-mercaptoethanol and 
analyzed by reverse zymography with trypsin (Fig 4). After affinity 
chromatography and elution, the antitrypsin activity appeared at 31 
kD and 29 kD in the ECM extract eluted from trypsin (Fig 4, lane 
2), but not from BSA (Fig 4, lane 3) and ethanolamine beads (Fig 
4 , Lan.e 4). Antitrypsin activity appeared in the unbound fractions 
from these control columns (not shown). These results indicate that 
the inhibitors bound selectively to a trypsin affinity column and 
were recovered with slightly reduced sizes. Such a reduction in the 
molecular size of the inhibitors has been noted for other serine 
protease inhibitors [27,28]. 
Characteristics of ECM-Associated Serine Protease Inhibi-
tors The antitrypsin activities of the ECM-associated inhibitors 
were tested for their sensitivity to heat and reduction with dithio-
threitol (Fig 5). Compared to the control (Fig 5 , lane 1), boiling the 
inhibitors for 5 min did not result in loss of activity (Fig 5, lane 2). 
However, antitrypsin activity was destroyed when the inhibitors 
were boiled for 5 min in the presence of 2 mM (Fig 5 , lane 3) or 5 
mM (Fig 5, lane 4) dithiothreitol. These observations indicate that 
the activity of the ECM-bound inhibitors requires intact disulfide 
bonds. 
DISCUSSION 
The molecular sizes and certain biochemical properties of the 
ECM-associated 33-kDa, 31-kDa, and 27-kDa serine protease 
inhibitors suggest that these are not related to the known serum 
serine protease inhibitors. Serum contains a number of serine 
protease inhibitors, which have been characterized extensively 
[27,28]. These include al-antitrypsin (53 kDa), a2- antiplasmin (70 
kDa), al - antichymotrypsin (58-68 kDa), antithrombin III (53 
kDa), PAI-l (50 kDa), PAI-2 (50-60 kDa), and protease nexin- l 
(43-50 kDa). All of these inhibitors belong to the superfamily of 
serine protease inhibitors called Serpins. It has been reported that 
the binding of Serpins to their target enzymes is SDS-resistant and 
that these inhibitors are inactivated irreversibly after such binding 
[29]. Analysis of PAI-l , PAI-2, and protease nexin-l by gelatin 
reverse zymography with crypsin revealed that these inhibitors did 
not appear as gelatin bands. * 
Serum also contains a member of the Kunitz superfamily of 
* Rao CN, unpublished observations . 
VOL. 104, NO.3 MARCH 1995 
inhibitors called inter-a-trypsin inhibitor (Ial) [30,31]. In contrast 
to Serpins, lal (160-180 kDa) binding to trypsin is SDS-disso-
ciable, and lal is active after binding to its target enzymes. The 
ECM-associated 33-kDa, 31-kDa, and 27-kDa trypsin inhibitors 
share several properties with the Kunitz family inhibitors: 1) The 
enzyme-bound inhibitors can be eluted with acid in active form; 2) 
the antitrypsin activity of the inhibitors is heat stable; and 3) urine 
trypsin inhibitor, lal, and aprotinin are readily detected by reverse 
zymography. 
It has been shown that the fragments of lal are fully active as 
trypsin inhibitors [30]. Although the ECM-associated inhibitors are 
functionally similar to lal, polyclonal antiserum to lal did not label 
the 33-kDa, 31-kDa, and 27-kDa inhibitors by immunoblotting or 
immunoprecipitation analyses. Similarly, polyclonal antibodies to 
six Serpin family inhibitors did not label these matrix-associated 
inhibitors.t Therefore, the 33-kDa, 31-kDa, and 27-kDa ECM-
associated inhibitors may be novel. Normal human serum and 
bovine pituitary extracts do not contain these inhibitors. 
The ECM association of the 33-kDa, 31-kDa, and 27-kDa 
inhibitors may have physiologic importance. It is not known which 
component(s) of the ECM of skin cells (collagen types I, III, IV, and 
V; glycoproteins such as laminin, fibronectin, and entactin; and 
proteoglycans such as heparan sulfate and chondroitin sulfate) 
interact with these inhibitors. We found that the ECM-associated 
inhibitors from t12 fibroblasts can be extracted with 1 M NaCI. 
Similarly, 1 M NaCI eluted the heparin sepharose affinity-column-
bound inhibitors. t These results suggest that heparan sulfate pro-
teoglycan may be the matrix component binding the 33-kDa, 
31-kDa, and 27-kDa inhibitors. The specific association of these 
inhibitors with the ECM of skin cells suggests that they may have a 
role in the inhibition of cell surface plasmin. Studies have shown 
that the cell surface plasmin is resistant to inhibition by serum 
plasmin inhibitors, namely a2-antiplasmin and a2-macroglobulin 
[32-34]. In additiun to degrading ECM components and fibrin [35], 
plasmin has been shown to activate MMP-1 [36,37], MMP-3 [37], 
and latent transforming growth factor {3 [38]. Thus, it is of 
physiologic importance to investigate whether the ECM-associated 
33-kDa, 31-kDa, and 27-kDa inhibitors inhibit the cell surface 
plasmin. Such a role for these inhibitors identifies them as important 
modulators of cell migration during embryogenesis, neovascular-
ization, tumor invasion and metastasis, and wound healing. 
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